Response Pharmaceuticals has begun enrolling its first patients in a Phase 2 trial for RDX-002, a new small molecule iMTP inhibitor, targeting individuals stopping GLP-1 agonists.
Bright Peak Therapeutics has initiated dosing for the first patient in the Phase 1/2a clinical trial of BPT567, an innovative bifunctional PD1-IL18 immunoconjugate.
Wave Life Sciences reports the first successful therapeutic RNA editing in humans during the RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency.
Latigo Biotherapeutics has administered the first dose to a participant in its Phase 1 clinical trial for LTG-305, aimed at non-opioid pain management.
IgGenix has reported that the initial patient has been dosed in its Phase 1 trial, named "ACCELERATE Peanut," which is testing IGNX001 for peanut allergies.